Downloads: 42

Files in This Item:
File Description SizeFormat 
s13063-019-3570-6.pdf1.05 MBAdobe PDFView/Open
Title: The efficacy of a cyclin dependent kinase 9 (CDK9) inhibitor, FIT039, on verruca vulgaris: Study protocol for a randomized controlled trial
Authors: Nomura, Takashi
Sumi, Eriko  kyouindb  KAKEN_id  orcid https://orcid.org/0000-0002-5028-0499 (unconfirmed)
Egawa, Gyohei
Nakajima, Saeko
Toichi, Eiko
Uozumi, Ryuji  kyouindb  KAKEN_id  orcid https://orcid.org/0000-0002-9546-9869 (unconfirmed)
Tada, Harue  kyouindb  KAKEN_id
Nakagawa, Takayuki  kyouindb  KAKEN_id
Hagiwara, Masatoshi  kyouindb  KAKEN_id
Kabashima, Kenji
Author's alias: 野村, 尚史
角, 栄里子
江川, 形平
中島, 沙恵子
十一, 英子
魚住, 龍史
中川, 貴之
萩原, 正敏
椛島, 健治
Keywords: Cyclin dependent kinase 9 (CDK9)
Human papilloma virus (HPV)
Verruca vulgaris
FIT039
Issue Date: 9-Aug-2019
Publisher: Springer Science and Business Media LLC
Journal title: Trials
Volume: 20
Thesis number: 489
Abstract: Background: Human papilloma viruses (HPVs) infect squamous epithelial cells and form verrucous lesions, or warts. Besides the psychosocial problems caused by the disfiguring warts, a subset of HPVs can be the primary etiologic agent for malignancies such as cervical cancer. However, there is no curative antiviral therapy for HPV infection. We recently found that the viral RNA transcription of DNA viruses requires cyclin dependent kinase 9 (CDK9) in the host cells, and that FIT039, a specific inhibitor of CDK9, suppressed the proliferation of DNA viruses such as herpes simplex virus 1 (HSV-1), HSV-2, human adenovirus, human cytomegalovirus, hepatitis virus B, and HPVs. Here, we describe a protocol to evaluate the safety and antiviral effect of FIT039 on common warts in human skin. Methods and design: A multi-institutional, single-blind, placebo-controlled randomized phase I/II clinical trial was designed to evaluate the safety and efficacy of FIT039 on common warts on the extremities. A total of 44 adults with a primary diagnosis of verruca vulgaris on the extremities without serious comorbidities will be randomized into either the intervention group with an FIT039-releasing transdermal patch or a control group for a duration of 14 days. Outcomes will be assessed at baseline and postintervention. Participants will be further assessed at 2 months follow-up. The primary endpoint for efficacy is the resolution of the warts. The safety endpoint is the incidence of adverse events and adverse drug reactions. The secondary endpoints are changes in the dimensions of the wart, the cross-sectional area of the wart, and the number of clots within the area of the wart. Discussion: This study is the first to assess the efficacy of FIT039 and will contribute to the development of antiviral agents that can cure refractory common warts in immunocompromised patients. Trial registration: UMIN Clinical Trials, UMIN000029695. Registered on 1 November 2017.
Rights: This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
URI: http://hdl.handle.net/2433/245678
DOI(Published Version): 10.1186/s13063-019-3570-6
Appears in Collections:Journal Articles

Show full item record

Export to RefWorks


Export Format: 


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.